Aktienanalyse zu Viatris Inc (VTRS)VTRSViatris Inc

Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Viatris Inc (VTRS) is a good buy right now due to its current price of $17.64, which is significantly below the average analyst price target of $25 to $26, indicating a potential upside of 42% to 47%. Additionally, the forward P/E ratio of 6.38 suggests the stock is undervalued compared to its earnings potential, while the recent acquisition of Pacira BioSciences for $1.65 billion enhances its market position in non-opioid pain management, which could drive future revenue growth. However, a risk to consider is the 247.32% increase in hedge fund selling, indicating potential bearish sentiment from institutional investors.